Earnings report 📈 Stocks 🌍 GLOBAL

IceCure Medical Reports 83% U.S. Sales Growth for Nine Months Ended Sept 30

IceCure Medical saw U.S. sales jump 83% and expanded its commercial reach to 21 states, though rising R&D costs pushed the nine-month net loss to $12.9 million.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: ICCM → 4/10 (55% confidence).

📊 Affected Assets (1)

ICCM
Neutral 🤖 55%
📅 Short-term 🌍 GLOBAL · Explicit

Nine-month revenues rose 26% to $2.6 million with U.S. ProSense sales up 83% and commercial reach doubling to 21 states, which is clearly positive. However, net loss widened to $12.9 million from $10.8 million and R&D spend grew to $6.5 million, while cash of only $8.2 million raises funding questions. The good and bad largely offset each other.

Catalysts
  • • Nine-month revenues up 26% to $2.6 million versus $2.1 million in 2025
  • • U.S. sales grew 83% year over year and commercial reach expanded from 11 to 21 states
Risk Factors
  • • Net loss widened to $12.9 million from $10.8 million year over year
  • • Cash and cash equivalents of only $8.2 million as of September 30, 2026 against ongoing losses

🎯 Key Takeaways

  • Total revenue for the first nine months of 2026 rose 26% to $2.6 million.
  • U.S. commercial reach expanded to 21 states, up from 11 in the third quarter of 2025.
  • Net loss widened to $12.9 million for the nine-month period, compared to $10.8 million in 2025.
  • Research and development expenses increased to $6.5 million from $5.1 million year over year.
  • Cash and cash equivalents stood at $8.2 million as of September 30, 2026.

📝 Executive Summary

IceCure Medical reported a 26% increase in total revenue to $2.6 million for the first nine months of 2026, driven by an 83% surge in U.S. sales. Despite this commercial expansion and a broader footprint across 21 states, the company's net loss widened to $12.9 million from $10.8 million in the prior-year period, with cash reserves totaling $8.2 million as of September 30, 2026.

❓ FAQ

How did IceCure's business perform in the first nine months of 2026?

Revenues grew about 26% to $2.6 million, U.S. sales rose 83% year over year, and the company reached 21 U.S. states, up from 11 states a year earlier.

Is the company profitable?

No. The net loss widened to $12.9 million for the nine months ended September 30, 2026, from $10.8 million in the prior-year period, and cash stood at about $8.2 million.